



Thursday, March 6, 2025

1:30 – 1:35 pm	<p>Welcome Mikkael Sekeres, MD, MS, AAMDSIF Medical Advisory Board Chair Olatoyosi Odenike, MD, AAMDSIF Medical Advisory Board Vice Chair</p>
1:35 – 2:05 pm	<p>Keynote Address Kelly Norsworthy, MD Deputy Division Director, FDA Division of Hematologic Malignancies Associate Director of Research Mentorship, FDA Oncology Center of Excellence</p>
2:05 – 2:35 PM	<p>Corporate Partner Reports</p>
2:35 – 3:55 pm	<p>Aplastic Anemia Session Moderator: Emma Groarke, MD, National Heart, Lung, and Blood Institute</p> <p>Clonal dynamics after IST for immune AA - Bhavisha Patel, MD, NHLBI</p> <p>HCT for AA Clonal Evolution – Pedro Prata, MD, PhD, Centre Hospitalier Universitaire de Limoges, France</p> <p>The role of T-regulatory cells in the pathophysiology and therapy for immune BMF – Tapan Kadia, MD, MD Anderson</p> <p>Role of alternative TPO agonists in immune BMF – Zoe McQuilten, MD, Monash University, Australia</p>
3:55 – 4:10 pm	<p>Break</p>
4:10 – 4:40 pm	<p>Corporate Partner Reports</p>
4:40 – 6:00 pm	<p>PNH Session Moderator: Phil Scheinberg, MD, Hopital A Beneficencia, Sao Paulo, Brazil</p> <p>Factor B inhibitor – Regis Peffault deLatour, MD, PhD, Hopital Saint-Louis, Paris</p> <p>Alternate C5 inhibitors - Austin Kulasekararaj, Kings College, London</p> <p>Masp-3 inhibitor – Morag Griffin, MBChB, FRCPath, St. James University Hospital, Leeds, UK</p> <p>C3 inhibitors - Carlos DeCastro, MD, Duke University</p>
6:00 – 8:30 pm	<p>Welcome Reception and Poster Session</p>

Friday, March 7, 2025

8:00 – 9:00 am	Breakfast
9:00 – 9:30 am	Corporate Partner Reports
9:30 – 10:50 am	MDS Session Moderated by Olatoyosi Odenike, MD, University of Chicago Targeting pre-mRNA splicing in MDS – Salima Benbarche, PhD, Memorial Sloan Kettering Allogeneic stem cell transplantation in MDS - patient selection and role of geriatric assessment in transplant optimization – Mariam Nawas, MD, University of Chicago Measurable residual disease assessment in MDS and clinical relevance? – R. Coleman Lindsley, MD, PhD, Dana-Farber
10:50 – 11:00 am	Break
11:00 – 11:30 am	Corporate Partner Reports
11:30 am – 12:50 pm	AML Session Moderated by Mikkael Sekeres, MD, MS, University of Miami HMA + Ven vs. 7+3 vs. liposomal cytarabine/daunorubicin for secondary AML – <i>Uma Borate, MD, Ohio State University</i> Using MRD to Make AML Treatment Decisions – Chris Hourigan, DM, DPhil, FRCP, Virginia Tech FBRI Cancer Research Center Transplant Yes or No for Older Adults with AML: What factors make the decision? – Noa Holtzman, MD, University of Miami The best approach for good-risk AML in Older Adults – Kah Poh (Melissa) Loh, MD, MS, FACCC, FASCO, University of Rochester
1:00 – 2:00 pm	Closing Lunch